Skip to main content

Table 1 Patient characteristics

From: Prognostic value of resting coronary sinus flow determined by phase-contrast cine cardiovascular magnetic resonance in patients with known or suspected coronary artery disease

  All patients N = 1212 Patients with known CAD N = 693 Patients with suspected CAD N = 519 *P-value
Clinical variables
 Age, years 69 ± 10 69 ± 10 68 ± 11 0.37
 Male 921 (76%) 554 (80%) 367 (71%) < 0.005
 BMI, kg/m2 24 ± 3 24 ± 3 24 ± 4 0.49
 Hypertension 823 (68%) 483 (70%) 340 (66%) 0.13
 Dyslipidemia 821 (68%) 488 (70%) 333 (64%) 0.021
 Diabetes mellitus 366 (30%) 229 (33%) 137 (26%) 0.012
 Current smoking 79 (7%) 55 (8%) 24 (5%) 0.021
Blood test
 HbA1c, % 6.0 ± 0.8 6.1 ± 0.9 5.9 ± 0.7 0.005
 LDL cholesterol 99 ± 28 94 ± 27 107 ± 30 < 0.001
 eGFR 66 ± 16 67 ± 16 66 ± 15 0.42
CMR variables
 LVEDV, mL 131 ± 46 128 ± 42 134 ± 51 0.053
 LVESV, mL 57 ± 37 55 ± 33 59 ± 42 0.24
 LV mass, g 95 ± 34 92 ± 36 99 ± 31 < 0.001
 LVEF, % 60 ± 12 60 ± 12 59 ± 12 0.84
 Presence of LGE 591 (49%) 439 (63%) 152 (29%) < 0.001
 LGE, % 7.9 ± 9.0 9.6 ± 9.6 5.9 ± 7.7 < 0.001
 Presence of ischemia 516 (43%) 195 (28%) 321 (62%) 0.002
 > 10% ischemia 258 (21%) 175 (25%) 83 (16%) < 0.001
  1. Data are expressed as mean ± SD or number (%)
  2. *P-value represents significance of difference between patients with known CAD and suspected CAD
  3. BMI body mass index, CAD coronary artery disease, CFR coronary flow reserve, CMR cardiac magnetic resonance, eGFR estimated glomerular filtration rate, LDL low-density lipoprotein, LGE late gadolinium enhancement, LV left ventricular, LVEDV left ventricular end-diastolic volume, LVEF left ventricular ejection fraction, LVESV left ventricular end-systolic volume, MACE major adverse cardiac events